Ernexa Therapeutics (ERNAW) Current Deferred Revenue (2010 - 2025)
Ernexa Therapeutics (ERNAW) reported Current Deferred Revenue of $5.3 million for Q1 2025, up 2722.75% on a YoY basis from $189000.0 in Q1 2024, and up 2722.75% quarter-over-quarter from $189000.0 in Q2 2024.
Ernexa Therapeutics (ERNAW) Current Deferred Revenue (2010 - 2025) Analysis & Trends
Ernexa Therapeutics has reported Current Deferred Revenue for 14 years, with the latest figure at $5.3 million in Q1 2025.
- For the quarter ending Q1 2025, Current Deferred Revenue rose 2722.75% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2025 stood at $5.3 million (up 2722.75% YoY), and the FY2023 full-year result was $190000.0, changed N/A from the prior year.
- Current Deferred Revenue for Q1 2025 stood at $5.3 million, up from $189000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $5.3 million in Q1 2025, with the low at $189000.0 in Q1 2024.
- Historically, Current Deferred Revenue has averaged $1.3 million across 3 years, with a median of $190000.0 in 2023.
- The largest YoY upside for Current Deferred Revenue was 2722.75% in 2025 against a maximum downside of 2722.75% in 2025.
- Ernexa Therapeutics' Current Deferred Revenue stood at $190000.0 in 2023, then retreated by 0.53% to $189000.0 in 2024, then surged by 2722.75% to $5.3 million in 2025.
- The last three Current Deferred Revenue figures came in at $5.3 million (Q1 2025), $189000.0 (Q2 2024), and $189000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ernexa Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 5.34 Mn |
| Jun 30, 2024 | 189,000.00 |
| Mar 31, 2024 | 189,000.00 |
| Dec 31, 2023 | 190,000.00 |
| Sep 30, 2023 | 349,000.00 |
| Dec 31, 2020 | 76,000.00 |
| Sep 30, 2020 | 120,000.00 |
| Mar 31, 2020 | 383,000.00 |
| Dec 31, 2019 | 460,000.00 |
| Sep 30, 2019 | 743,000.00 |
| Jun 30, 2019 | 518,000.00 |
| Mar 31, 2019 | 1.19 Mn |
| Dec 31, 2018 | 1.27 Mn |
| Jun 30, 2018 | 83,000.00 |
| Mar 31, 2018 | 132,000.00 |
| Dec 31, 2017 | 182,000.00 |
| Sep 30, 2017 | 3.71 Mn |
| Jun 30, 2017 | 3.84 Mn |
| Mar 31, 2017 | 1.04 Mn |
| Dec 31, 2016 | 1.06 Mn |